Author + information
Most breast cancer patients are treated with anthracycline and some with trasztuzumab contributing to an ongoing burden of heart failure in survivors. The role of race in the development of heart failure in breast cancer survivors is unknown. Thus, the goal is to determine whether race influences the risk of heart failure in Breast Cancer survivors.
The US Surveillance Epidemiology and End Results (SEER) cancer registries linked with Medicare data was used to identify women diagnosed with breast cancer. Kaplan-Meier survival analysis and Cox regression analysis were performed to determine the effect of baseline variables (including race) on the risk of heart failure in women with breast cancer.
Of 26,347 women with breast cancer from 1973-2007, 16% (N = 4183) were later diagnosed with heart failure of whom, 81% were white, 14% were black, 2% were Asian, 1% were Hispanic and 2% were of unknown origin. Kaplan-Meier survival analysis stratified according to race was significantly associated with heart failure (Logrank p<0.0001). In multivariable Cox analysis, stratification by race had significant effect on predicting heart failure where blacks had a 1.4-fold higher risk of developing heart failure than whites (hazard ratio, 1.4; 95% Confidence Interval, 1.3-1.6; p<0.0001) adjusted for age, chemotherapy, cardioprotective drugs, hypertension and diabetes.
Black women diagnosed with breast cancer have a higher risk of developing heart failure than whites.
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.-10:45 a.m.
Session Title: Dilated Cardiomyopathies: From Peripartum, Cancer Therapy, Familial Cardiomyopathies to Cardiac Amyloidosis
Abstract Category: 15. Heart Failure: Clinical
Presentation Number: 1134-275
- 2013 American College of Cardiology Foundation